Remus Pharmaceuticals Q4 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹1,029 Cr
- P/E
- 27.83
- ROE
- 12.19%
- Price to sales
- 1.21
- Debt to equity
- 0.08
- 52W high / low
- ₹1,021 / ₹583
- EBITDA margin
- 6.64%
- Net profit margin
- 5.41%
- Promoter holding
- 70.95%
- Sales (last year)
- ₹854 Cr
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
Guidance scorecard · Q4 FY26 call
What Remus Pharmaceuticals Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
20–40%- Revenue Growth: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets.
- B2C Segment: Expected to grow to ~30% of total revenue in FY 2027, doubling from 14%-15% in FY 2026, driven by new product launches, especially in Bolivia and other Latin American markets.
- B2B Segment: Anticipated to grow at 25%-30% YoY, focusing on institutional and distributor-level sales.
- Geographical Expansion: Increasing presence in over 40 countries; new markets include Myanmar, Nicaragua, Macedonia, Madagascar, with active filings in Peru, Asia-ASEAN, Middle East, Europe, and Africa.
- Product Pipeline: Launching 26 products in Bolivia soon; filing semaglutide tablets and injections in 3-4 non-patented emerging markets with plans for patented markets as patents expire (2027-2029).
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what Remus Pharmaceuticals Ltd said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Remus Pharmaceuticals is focused on an asset-light model, primarily outsourcing manufacturing to CMOs rather than investing heavily in fixed assets.
- The company is creating infrastructure that may not be visibly asset-heavy but is critical from a brand-building perspective.
- There have been investments in R&D (~Rs. 4 crores) including bioequivalence studies and clinical trials to access markets requiring human clinical data, enabling better margins.
- The strategy is to continue without owning manufacturing assets, similar to models like Eris Pharmaceuticals before it acquired plants.
- New subsidiaries, such as Espee Global Clinical Trial Services, are expected to become operational soon, which will contribute partially to margins.
2 more points from Remus Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what Remus Pharmaceuticals Ltd said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Rising- The company holds inventory levels based on anticipated orders, especially in chronic therapy products, maintaining 4-6 months of stock to ensure uninterrupted supply.
- The US and Latin American subsidiaries contribute significantly to working capital investment linked to inventory and distribution.
- Product launches, such as 26 products planned for Bolivia in the next 2-3 months, indicate expanding order fulfillment.
- The company is filing and preparing products, including Semaglutide and Pegfilgrastim PEG, for launches across multiple countries, some of which are awaiting patent expiries.
2 more points from Remus Pharmaceuticals Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Remus Pharmaceuticals Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Remus Pharmaceuticals Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Remus Pharmaceuticals Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Remus Pharmaceuticals Ltd
Profit & Loss
Annual income statement trend
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales + | 213 | 620 | 854 |
| Expenses + | 184 | 575 | 797 |
| Operating Profit | 29 | 46 | 57 |
| OPM % | 14% | 7% | 7% |
| Other Income + | 3 | 5 | 7 |
| Interest | 0 | 1 | 1 |
| Depreciation | 1 | 2 | 3 |
| Profit before tax | 30 | 47 | 59 |
| Tax % | 20% | 19% | 22% |
| Net Profit + | 24 | 38 | 46 |
| EPS in Rs | 17.69 | 24.64 | 31.39 |
| Dividend Payout % | 4% | 3% | 2% |
Financials of Remus Pharmaceuticals Ltd
Balance Sheet
Capital structure and asset base
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 1 | 6 | 12 |
| Reserves | 156 | 250 | 339 |
| Borrowings + | 14 | 23 | 27 |
| Other Liabilities + | 161 | 154 | 201 |
| Total Liabilities | 333 | 433 | 579 |
| Fixed Assets + | 14 | 16 | 18 |
| CWIP | 0 | 0 | 8 |
| Investments | 105 | 186 | 275 |
| Other Assets + | 215 | 231 | 277 |
| Total Assets | 333 | 433 | 579 |
Financials of Remus Pharmaceuticals Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity + | 1 | 7 | 18 |
| Cash from Investing Activity + | -25 | -11 | -15 |
| Cash from Financing Activity + | 28 | 6 | 1 |
| Net Cash Flow | 4 | 3 | 5 |
| Free Cash Flow | -11 | 3 | 4 |
| CFO/OP | 25% | 32% | 49% |
Financials of Remus Pharmaceuticals Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 198 | 64 | 60 |
| Inventory Days | 96 | 35 | 35 |
| Days Payable | 209 | 49 | 37 |
| Cash Conversion Cycle | 85 | 50 | 58 |
| Working Capital Days | 98 | 54 | 57 |
| ROCE % | 20% | 17% |
Guidance history
How Remus Pharmaceuticals Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 20–40% | Flat | Planned | — | Rising |
| Q2 FY26 call → | 20–40% | Up 2%+ | Planned | — | — |
| Q4 FY25 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
40 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +30.1% | 78% |
| Last 6 months | +27.5% | 79% |
| Last 3 months | +21.8% | 87% |
The price is 35.9% below its all-time high of ₹1,362.28 (11 Oct 2024). Stocks more than 20% below their peak have their score halved, so 80 became 40.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Remus Pharmaceuticals Ltd: 0.4 × 78 + 0.4 × 79 + 0.2 × 87 = 80, halved to 40 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Remus Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY